Pharmacological interventions for non-ulcer dyspepsia

Area of Science:

• Gastroenterology
• Clinical Pharmacology

Background:

• Non-ulcer dyspepsia (NUD) is a common cause of upper gastrointestinal symptoms with unclear pathophysiology and treatment.
• Dyspepsia management in the UK incurs significant annual costs, highlighting the need for effective therapies.

Purpose of the Study:

• To evaluate the effectiveness of six drug classes—antacids, histamine H2 antagonists (H2RAs), proton pump inhibitors (PPIs), prokinetics, mucosal protecting agents, and antimuscarinics—for NUD.
• To assess improvements in individual or global dyspepsia symptom scores and quality of life.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Searches conducted across multiple databases (CCTR, MEDLINE, EMBASE, CINAHL, SIGLE) and expert consultations.
• Inclusion criteria focused on RCTs comparing specified drug classes against each other or placebo for NUD.

Main Results:

• Prokinetics, H2RAs, and PPIs demonstrated significantly greater effectiveness than placebo in improving NUD symptoms.
• Bismuth salts showed a trend towards superiority over placebo, though not statistically significant.
• Antacids and sucralfate did not show statistically significant benefits over placebo; publication bias may affect prokinetic and H2RA findings.

Conclusions:

• Anti-secretory therapies show potential efficacy for NUD.
• Interpreting prokinetic therapy effectiveness is challenging due to potential publication bias.
• Further economic analyses are needed, emphasizing inexpensive and well-tolerated NUD treatments.